MedTrace Logo

Genomic and Proteomic Analyses of Apoptosis Mechanisms in Diseased Peri-implant Tissue

NCT06865976 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 72

Last updated 2025-03-10

No results posted yet for this study

Summary

A total of 72 individuals were included in the study: 23 with peri-implant mucositis, 25 with peri-implantitis, and 24 healthy controls. Clinical and radiological parameters, including keratinized mucosa width, modified bleeding index, probing depth, modified plaque index, modified gingival index, and marginal bone loss percentage, were recorded. Granulation tissues were collected during peri-implant disease treatments, while healthy control tissues were obtained during the second stage of implant surgery. Tissue levels of Bcl-2 family pro-apoptotic and anti-apoptotic proteins were measured using multiplex immunoassay, and tissue levels of P. gingivalis gingipain and T. denticola dentilisin with immunoblotting.

Conditions

  • Apoptosis
  • Apoptosis Regulatory Proteins
  • Proteases
  • Peri-Implantitis and Peri-implant Mucositis

Interventions

PROCEDURE

Non-Surgical Intervention

For non-surgical treatment of peri-implant mucositis, granulation tissues were removed by titanium curettes (Hu-Friedy, Titanium Implant Scaler Mini-Five, Chicago, IL, USA) during mechanical debridement under local anesthesia

PROCEDURE

Surgical peri-implant therapy

In cases requiring surgical intervention for peri-implantitis, mucoperiosteal flaps were elevated on both vestibular and oral aspects after administration of local anesthesia (articaine with epinephrine 1:200,000) to expose the peri-implant defect. Granulation tissue from the bony defect area was meticulously excised using by titanium curettes (Hu-Friedy, Titanium Implant Scaler Mini-Five, Chicago, IL, USA).

PROCEDURE

Second stage surgery

Healthy peri-implant mucosa samples were obtained during the second-stage surgery of implant placement procedures. These samples consisted of incisional biopsies of peri-implant mucosa in direct contact with the implant surface.

Sponsors & Collaborators

  • University of Turku

    collaborator OTHER

  • University of Helsinki

    collaborator OTHER

  • Sakarya University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2022-06-01
Completion
2024-09-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06865976 on ClinicalTrials.gov